1 min read

Disgraceful. That’s the best description of findings that unnecessary and damaging shortages of some cancer drugs have led to relapses among kids fighting cancer at St. Jude Children’s Hospital and elsewhere.

It wasn’t the hospital’s fault. In fact, it was St. Jude that blew the whistle.

The results are shocking. Children get much sicker and suffer from more severe side effects. Sometimes, their cancer returns.

It doesn’t have to be that way. Stronger regulation and oversight of drug supplies, plus better product and inventory management by private drug manufacturers could fix it.

— The Commercial Appeal, Memphis



Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.